Exelixis's SWOT analysis: stock poised for growth amid pipeline progress

Exelixis (EXEL) has delivered a 94.31% stock return over the past year, underpinned by strong financial health and robust sales of its oncology drug, cabozantinib (Cabo), which posted Q4 2024 sales of $510 million. The company projects 2025 total revenue between $2.15 billion and $2.25 billion, with net product revenue growth of approximately 10.8% at the midpoint, driven by continued Cabo performance and a pending FDA decision for its use in neuroendocrine tumors (NET) by April 2025. Future growth is heavily reliant on zanzalintinib (Zanza), a next-generation inhibitor in pivotal trials for colorectal cancer and renal cell carcinoma, which analysts project could reach $5 billion in peak sales across indications, though competitive pressures and clinical trial outcomes remain key risks.

Analysis

Exelixis (EXEL) demonstrates a robust financial and operational profile, underscored by a 94.31% stock return over the past year and a perfect Piotroski Score of 9. The company's current strength is anchored by its lead oncology drug, cabozantinib, which exceeded analyst expectations with Q4 2024 sales of approximately $510 million and is driving strong market share gains in renal cell carcinoma (RCC). The company's 2025 total revenue guidance of $2.15 billion to $2.25 billion, implying a 10.8% midpoint growth in net product revenue, appears supported by this momentum and a significant near-term catalyst: a pending FDA decision by April 3, 2025, for cabozantinib's label expansion into neuroendocrine tumors (NET). The long-term growth narrative is critically dependent on the pipeline, specifically the next-generation inhibitor zanzalintinib. This candidate is positioned as a successor to cabozantinib with potentially improved tolerability and is in pivotal trials for colorectal cancer (CRC) and RCC, with key data readouts expected in the second half of 2025. While analysts project zanzalintinib could become a $5 billion opportunity, significant execution risk remains, centering on clinical trial outcomes and navigating the highly competitive oncology market, which contributes to the wide variance in analyst price targets.

Key Decisions for Investors

• Investors should monitor the FDA's decision on cabozantinib for neuroendocrine tumors, due by April 3, 2025, as an approval represents a significant near-term growth catalyst not fully factored into guidance.
• The company's long-term value is heavily tied to zanzalintinib; therefore, closely watch for pivotal clinical trial updates in H2 2025, particularly for colorectal cancer, as these results will be a major inflection point for the stock.
• While fundamentals are strong, with a 96.78% gross profit margin and high returns on capital, the reliance on a single product and the binary risk of clinical trials for its successor warrant careful position sizing.
• Given the stock is trading below some fair value estimates despite its recent run-up, investors could consider the current valuation an entry point, but must be prepared for volatility tied to the pipeline's progress and competitive pressures.